secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2025-06-04T23:59:59+00:00
Accession:  0001213900-25-051144
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma shareholders approve all four proposals including related-party land deal
--------------------------------------------------------------------------------

- 11 directors re-elected with ~5.9M votes for each; 18,525 withheld per director.
- Simon & Edward, LLP ratified as auditor for FY2025 with 5,903,606 votes for.
- Land purchase from director Shuling Jiang approved (5,832,130 for); may exceed 20% of outstanding shares.
- Equity incentive plan increased to 15% of outstanding shares with annual auto-increase approved (5,691,168 for).
- Quorum of 5,917,309 shares (35.27% voting power) present for annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390025051144/0001213900-25-051144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390025051144/ea024460401-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-051144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer